An open label, single institute, single arm trial of efficacy and safety of the anti-RANKL monoclonal antibody (Denosumab) for patients with steroid-induced osteoporosis
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Denosumab (Primary)
- Indications Male osteoporosis; Osteoporosis
- Focus Biomarker; Therapeutic Use
- Acronyms OSRANKLE-SIO
- 14 Feb 2018 Status changed from recruiting to completed.
- 13 Aug 2013 New trial record